MET and non-small cell lung carcinoma: This review focuses on the latest updates in the field of EGFR-mutant advanced NSCLC treatment, addressing the EGFR-dependent and independent mechanisms of resistance to EGFR-TKIs, including MET and HER gene amplifications, the role of mutations coding for the RAS and PIK3CA genes, as well as other less common genetic alterations.